PF-06741086 Multiple Dose Study in Severe Hemophilia

Completed · Phase 2

Conditions studied: Hemophilia A or B

In brief

This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.

Key facts

Study ID

NCT02974855

Run by

Pfizer

People needed

27

Starts

2017-03-08

Expected to finish

2018-12-03

Last updated by the study team

2019-12-04

Who can join

Age: 18 and older, up to 64. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Severe hemophilia A or B (Factor VIII or Factor IX activity ≤ 1%), including patients with inhibitors to Factor VIII or Factor IX
• Episodic (on-demand) treatment regimen prior to screening
• At least 6 acute bleeding episodes during the 6-month period prior to screening

You may not qualify if…

• Known coronary artery, thrombotic, or ischemic disease
• Currently receiving treatment for acute bleeding episodes with APCC and cannot substitute treatment with rFVIIa

Where it is running

• UC Denver Hemophilia and Thrombosis Center - Pharmacy — Aurora, Colorado, United States
• UC Denver Hemophilia and Thrombosis Center — Aurora, Colorado, United States
• Pharmacy — Chicago, Illinois, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Hospital Dr. Sotero del Rio — Santiago, Chile
• Klinicki bolnicki centar Zagreb — Zagreb, Croatia
• Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne — Gdansk, Poland
• Phoenix Pharma (Pty) Ltd — Port Elizabeth, Eastern Cape, South Africa
• Haemophilia Comprehensive Care Centre — Johannesburg, Gauteng, South Africa
• UniversitatsSpital Zurich, Klinik fur Hamatologie — Zurich, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.